Merus (MRUS) Company Report

Merus's lead product candidate, Petosemtamab, is advancing with Phase 3 trials enrolling for recurrent/metastatic head and neck squamous cell cancer (r/m HNSCC) and initial interim data showing robust antitumor activity in metastatic colorectal cancer (mCRC). Topline readouts for one or both HNSCC Phase 3 trials are expected in 2026.
The company's first product, Bizengri® (zenocutuzumab), has received accelerated approval from the U.S. FDA for NRG1+ pancreatic adenocarcinoma and non-small cell lung cancer (NSCLC).
Merus reported a strong cash position of $817 million in cash and cash equivalents, which is expected to fund the company at least into 2028.
The clinical pipeline also features MCLA-129, which has demonstrated strong clinical activity in EGFRm NSCLC and METex14 NSCLC, with a 2L+ EGFRm NSCLC combination with chemotherapy enrolling.

Oct 31, 2025, 2:00 PM

Merus N.V. Foundation Supports Genmab Acquisition

MRUS

M&A

Takeover Bid

Merus N.V. and Stichting Continuïteit Merus entered into a Foundation Support Agreement on September 29, 2025.
The Foundation supports the proposed acquisition of Merus by Genmab, believing the transactions do not threaten the interests of the Company, its businesses, or its stakeholders.
Merus's Board of Directors has unanimously approved the transaction, determining it to be in the best interests of the Company and its stakeholders, and recommends shareholders accept the offer.
Genmab intends to acquire all shares of Merus for $97.00 per share in an all-cash transaction, representing a total value of approximately $8.0 billion.
The tender offer is anticipated to close by early in the first quarter of 2026.

Sep 29, 2025, 12:30 PM

Genmab Nears $5.2B Merus Acquisition

MRUS

M&A

Takeover Bid

Danish biotechnology company Genmab is in advanced acquisition talks to acquire Dutch biotech firm Merus, valued at approximately $5.2 billion.
Merus's market value has surged over 60% this year due to promising clinical trial results of its bispecific antibody petosemtamab, which showed a 63% response rate in head and neck cancer treatments.
Genmab, with a market capitalization near $18.5 billion, aims to strengthen its oncology pipeline through this acquisition, which would be its largest ever.
Despite strong liquidity and low debt levels, Merus has faced operational challenges, including a revenue decline of 23.8% over the past three years and significant negative operating (-619.33%) and net margins (-685.64%).
The completion of the Genmab deal remains uncertain, despite multiple takeover offers for Merus and potential imminent announcement.

Sep 28, 2025, 10:18 PM

Earnings Transcripts

Quarterly earnings call transcripts for Merus.

Get instant answers from SEC filings, earnings calls & more

Get instant analysis when filings drop